Behavioral health company Acadia Healthcare (NASDAQ: ACHC) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.2% year on year to $869.2 million. The company expects the full year’s revenue to be around $3.33 billion, close to analysts’ estimates. Its non-GAAP profit of $0.83 per share was 17.4% above analysts’ consensus estimates.

Is now the time to buy ACHC? Find out in our full research report (it’s free).

StockStory’s Take

Acadia Healthcare’s second quarter saw revenue and adjusted profit beat Wall Street expectations, but market reaction was sharply negative due to declining margins and cautious management commentary on Medicaid volumes. CEO Christopher Hunter cited weaker Medicaid volumes in acute care and ongoing challenges at underperforming facilities as key headwinds. He explained, “The primary driver of volume coming in below our expectations really was the weaker Medicaid volumes in our acute care business.” Management acknowledged that local market pressures and evolving utilization patterns among managed Medicaid plans contributed to the softness.

Looking ahead, Acadia Healthcare’s updated guidance reflects management’s caution around softer volumes, higher start-up costs, and continued uncertainty in the Medicaid landscape. CFO Heather Dixon pointed to a pull-forward of start-up losses due to accelerated facility openings, adding, “We are experiencing those incremental start-up costs earlier in the year than what we would have previously anticipated.” Management also flagged policy changes such as the One Big Beautiful Bill Act and evolving payer dynamics as factors that could influence growth, with a focus on mitigating risk through disciplined capital allocation and operational adjustments.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to a combination of robust growth in commercial and Medicare volumes, headwinds in Medicaid patient volume, and higher costs associated with rapid facility expansion.

• Medicaid volume softness: Weaker Medicaid volumes in acute care were a main driver of patient volume coming in below expectations, with CEO Christopher Hunter noting evolving utilization patterns among managed Medicaid plans and increased admissions scrutiny.
• Commercial and Medicare strength: Despite Medicaid headwinds, Acadia saw a 9% increase in commercial and 8% increase in Medicare volumes, aided by deliberate efforts to diversify payer contracts and reduce reliance on Medicaid.
• Start-up cost acceleration: Faster-than-planned bed openings led to $10 million in incremental start-up losses, attributed to construction projects progressing ahead of schedule, effectively pulling forward expenses from future periods.
• Supplemental payment dynamics: A favorable $51.8 million pre-tax benefit was recognized from the approval of the Tennessee Supplemental Payment Program, with management noting more than half of the $230 million in gross revenue from these programs could be at risk if policy shifts take effect in 2028.
• Labor cost improvements: Management reported improved labor cost trends with wage inflation stabilizing and a reduction in premium labor expenses, reflecting success in centralized recruitment and retention efforts.

Drivers of Future Performance

Acadia’s revised outlook emphasizes cautious volume growth, increased start-up costs, and policy-driven supplemental payments as the primary drivers of its forward guidance.

• Medicaid policy and payer behavior: Management expects ongoing headwinds from Medicaid volumes, citing continued uncertainty around payer authorization processes and potential impacts from the One Big Beautiful Bill Act. They noted that while exemptions are likely for much of their patient population, delays and stricter utilization management could persist.
• Capital allocation adjustments: In response to policy uncertainty and market conditions, Acadia is pausing select facility expansion projects to conserve capital and accelerate free cash flow generation. This shift is expected to reduce start-up losses in 2026 and improve near-term EBITDA.
• Supplemental payment variability: The company anticipates a $30 million to $40 million year-over-year tailwind from supplemental payments in 2025, but acknowledges that these payments are subject to change based on state and federal policy adjustments, introducing risk to revenue stability.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will focus on (1) the trajectory of Medicaid volumes and any further changes in payer authorization practices, (2) the pace and profitability of newly added beds as they ramp up, and (3) the impact of policy-driven supplemental payments, including potential adjustments stemming from the One Big Beautiful Bill Act. Progress on capital allocation discipline and cost management will also be key signposts for Acadia’s operational resilience.

Acadia Healthcare currently trades at $20.40, down from $21.79 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.